Table 4.
Hazard Ratio for Outcome Compared Between GD Cohort and Non-GD Cohort by Follow-Up Duration
| |
Non-GD cohort |
GD cohort |
|
|
||||
|---|---|---|---|---|---|---|---|---|
| Follow-up time (years) | Event | PY | Ratea | Event | PY | Ratea | IRR [CI] | Adjusted HRb[CI] |
| Breast | ||||||||
| ≤3 | 33 | 53,834 | 0.61 | 17 | 13,471 | 1.26 | 2.06 (1.87, 2.27)*** | 2.03 (1.13, 3.67)* |
| 3–6 | 29 | 38,658 | 0.75 | 9 | 9743 | 0.92 | 1.23 (1.09, 1.39)*** | 1.21 (0.57, 2.56) |
| 6–9 | 25 | 24,027 | 1.04 | 8 | 6128 | 1.31 | 1.25 (1.09, 1.45)** | 1.31 (0.59, 2.92) |
| >9 | 10 | 11,104 | 0.90 | 5 | 2799 | 1.79 | 1.98 (1.64, 2.40)*** | 1.94 (0.66, 5.67) |
| Thyroid | ||||||||
| ≤3 | 10 | 53,834 | 0.19 | 39 | 13,471 | 2.90 | 15.6 (13.9, 17.5)*** | 16.0 (7.95, 32.1)*** |
| 3–6 | 4 | 38,658 | 0.10 | 7 | 9743 | 0.72 | 6.94 (6.18, 7.80)*** | 6.26 (1.82, 21.5)** |
| 6–9 | 4 | 24,027 | 0.17 | 4 | 6128 | 0.65 | 3.92 (3.43, 4.49)*** | 3.57 (0.86, 14.8) |
| >9 | 2 | 11,104 | 0.18 | 2 | 2799 | 0.71 | 3.97 (3.27, 4.82)*** | 3.89 (0.55, 27.6) |
a
Incidence rate (per 1000 person-years).
b
Multivariable analysis including sex, age, and comorbidities of diabetes, hypertension, and hyperlipidemia.
*
p<0.05, **p<0.01; ***p<0.001.